Results 41 to 50 of about 2,233 (157)

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3819-3830, November 2026.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles [PDF]

Background An increasing amount of evidence supports the relevance of epithelium across the wide spectrum of asthma pathobiology. On a clinical ground tezepelumab, selectively binding TSLP, a major epithelial cytokine, has demonstrated to be effective in
Senna, G, Vatrella, A., A. Vatrella, Rogliani, P., P. Rogliani, Vatrella, A, Carpagnano, E., Marco Caminati, Spanevello, A., Spanevello, A, E. Carpagnano, Rogliani, P, Carpagnano, E, A. Spanevello, G. Senna, Senna, G., Caminati, Marco, Vatrella A., Caminati M., Spanevello A., Rogliani P., Carpagnano E., Senna G.   +22 more
core   +3 more sources

Real‐World Treatment Escalation Patterns of Biologics and Functional Endoscopic Sinus Surgery in Chronic Rhinosinusitis (CRS): A Nationwide Database Study

International Forum of Allergy &Rhinology, EarlyView.
Omer Baker, Bita Naimi, Soraya Mehdipour, Adam S. Deconde, Carol H. Yan   +4 more
wiley   +1 more source

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1255-1265, November 2026.
Digital patients and in silico clinical trials offer new opportunities to advance pharmacological research, clinical development, and regulatory decision‐making by enabling the simulation of treatment effects prior to testing in patients. Among the most promising of these opportunities is the combined use of quantitative systems pharmacology (QSP) and ...
Thomas Klabunde, Ramon Hernandez, Piet H. van der Graaf, Tommaso Andreani   +3 more
wiley   +1 more source

Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?

Clinical and Translational Allergy, Volume 16, Issue 10, October 2026.
ABSTRACT Background Biologic therapies can control severe asthma and may modify its natural history beyond symptom control. However, step‐down is not standardized, and its safety has not been clearly established. Methods This single‐center retrospective cohort study reviewed adults with severe asthma on biologics (January 2019–May 2024).
Nagihan Orhan Özer, Betül Özdel Öztürk, Begüm Görgülü Akın, Ceren Kaplankıran, Şadan Soyyiğit   +4 more
wiley   +1 more source

Bucher indirect treatment comparison of phase 3 trials with dupilumab and tezepelumab in chronic rhinosinusitis with nasal polyps

Background: Biologic therapies significantly affect clinical outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNPs), including those with comorbid asthma.
Lipworth, Brian J., Greig, Robert, Suter, Philipp   +2 more
core   +1 more source

Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study

19451956Background: Tezepelumab, an mAb inhibiting thymic stromal lymphopoietin, is an upstream-targeted therapy with potential to inhibit multiple pathways in chronic spontaneous urticaria (CSU). Objective: We sought to evaluate tezepelumab efficacy and
Gorski, Kevin S., Corren, Jonathan, Hayama, Koremasa, Chon, Yun, Lima, Hermenio C., Maurer, Marcus, Bernstein, Jonathan A., Jain, Vipul, Ponnarambil, Sandhia S., Sofen, Howard L., McLaren, Julie, Molfino, Néstor A.   +11 more
core   +1 more source

One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study

, 2022
To assess the long-term safety of tezepelumab in Japanese patients with severe uncontrolled asthma. This phase III, 52-week, open-label, single-arm study (NOZOMI, NCT04048343) evaluated the safety/tolerability of subcutaneous (SC) tezepelumab 210 mg ...
Motohiro Ebisawa (832199), Nobuya Hayashi (5483219), Masaharu Shinkai (5581280), Satomi Takeuchi (12881367), Tatsuro Tokiyo (12881370), Mami Takikawa (12881373), Gun Almqvist (3626828), Gene Colice (5129612), Hiroshi Okada (417814), Yasushi Fukushima (12881364)   +9 more
core   +1 more source

Generative AI and Clinicians Show Comparable Prognostic Reasoning From Clinical Narratives in Biologic‐Treated CRSwNP

World Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 12, Issue 5, Page 645-654, October 2026.
ABSTRACT Objective To compare the ability of large language models (LLMs) and otolaryngologists to identify prognostic signals from brief clinical vignettes in CRSwNP. Methods In this blinded study, 68 adults initiating biologic therapy for CRSwNP (≥ 36 months follow‐up) were represented by standardized vignettes derived from documentation immediately ...
Sholem Hack, Chase Kahn, Ainhoa Garcia‐Lliberos, Cristina Rodriguez‐Prado, Ameen Biadsee, Maxime Fieux, Mark Liu, Eran Glikson, Masayoshi Takashima, Omar G. Ahmed, Raj Sindwani, Dennis M. Tang, Christopher R. Roxbury   +12 more
wiley   +1 more source

Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines

British Journal of Pharmacology, Volume 183, Issue 19, Page 5975-5991, October 2026.
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu, Ahsan Ullah, Jisun Kim, Mehedi Hasan Bappi, Yerim Heo, Jin Hee Ahn, Hyun‐Kyoung Kim, Han‐Jung Chae   +7 more
wiley   +1 more source